NewAmsterdam Pharma shows mixed financial results with significantly higher operating losses due to increased SG&A expenses, but improved net income despite a 50% revenue decline.
The company is burning through cash rapidly (down $282M to $490M) while scaling up operations as evidenced by 51% higher SG&A expenses, suggesting increased commercialization efforts ahead of potential drug approvals. The EMA's acceptance of Marketing Authorization Applications for obicetrapib in Europe represents meaningful regulatory progress that could justify the increased spending.
The financial picture shows a company in heavy investment mode with SG&A expenses surging 51% to $106.4M while revenue dropped 50% to $22.5M, resulting in significantly worse operating losses of $225.7M. However, net income actually improved 16% to a loss of $203.8M due to lower interest expenses and other factors. The company's cash position declined substantially by 37% to $490M, indicating significant cash burn as it advances toward commercialization, though the balance sheet remains relatively strong with reduced liabilities.
SG&A up 51% — significant increase in sales or administrative costs, monitor impact on operating leverage.
Revenue declined 50.6% — significant demand weakness or market share loss warrants investigation.
Cash declined 36.5% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.
Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.
Current assets declined 21.7% — monitor working capital adequacy and short-term liquidity.
Liabilities reduced 19.9% — deleveraging improves balance sheet strength and financial flexibility.
Current liabilities reduced — improved short-term financial position and working capital health.
Net income grew 15.6% — bottom-line growth signals improving overall business health.
Total assets contracted 11% — asset sales, write-downs, or balance sheet optimization underway.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →